rss
Br J Ophthalmol 2005;89:647 doi:10.1136/bjo.2005.bjjun05at%20a%20glance
  • BJO at a glance

BJO at a glance

  1. Creig Hoyt, Editor

      SIROLIMUS TREATMENT FOR UVEITIS

      Sirolimus was originally developed as an antibiotic. Its potential as an immunomodulatory agent has been established for the prevention of allograft rejection following solid organ transplantation. Shanmuganathan and co-workers report the use of sirolimus in eight patients with severe non-infectious uveitis. It appeared to be an effective and potent immunosuppressant treatment in these patients. See p 666

      DECREASED ANTIOXIDANT STATUS IN DIABETIC RETINOPATHY

      The formation and accumulation of advanced glycation end products (AGE) is known to progress during normal aging and is extremely accelerated in diabetes mellitus. Yokoi and co-workers report that in the vitreous of patients with diabetic retinopathy there are increased levels of advanced glycation end products. The vitreous levels of AGE and VEGF (vascular growth factor) …

      This Article

      Services

      1. Request permissions

      Responses

      1. Submit a response
      2. No responses published

      Social bookmarking

      Register for free content


      Free sample
      This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of BJO.
      View free sample issue >>

      Free archive
      The full back archive is now available for BJO. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
      Register to access the free archive >>

      Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.